Long COVID manifests across virtually every organ system. Understanding the full spectrum of symptoms — and the biological mechanisms that drive them — is the first step toward targeted, effective treatment.
Brain fog, impaired concentration and memory, slowed processing speed, persistent headaches, dizziness, tinnitus, visual disturbances, peripheral neuropathy, and difficulty finding words. These symptoms are strongly associated with impaired cerebral microcirculation and neuroinflammation.
Profound, debilitating exhaustion that does not improve with rest. Post-exertional malaise (PEM) -- a worsening of symptoms following physical or cognitive activity. Exercise intolerance and dramatically reduced stamina. These reflect mitochondrial dysfunction and impaired cellular energy metabolism.
Heart palpitations, chest pain and tightness, postural tachycardia syndrome (POTS), orthostatic intolerance, blood pressure instability, and reduced cardiac output during exertion. Endothelial dysfunction and autonomic dysregulation are primary drivers.
Persistent shortness of breath, dyspnea on exertion, air hunger, chronic cough, and reduced lung capacity -- often occurring even when standard chest imaging and pulmonary function tests appear normal. Microvascular damage in the pulmonary bed may explain these symptoms.
Abdominal pain, nausea, altered bowel habits, food intolerances, weight fluctuations, appetite changes, and new onset glucose dysregulation. Gut-brain axis disruption, altered microbiome composition, and intestinal permeability are implicated.
Reactivation of latent viruses (EBV, CMV, HHV-6), new-onset autoimmune phenomena, histamine intolerance, mast cell activation, recurrent infections, persistently elevated inflammatory markers, and lymph node tenderness.
Beyond the major system categories above, Post-COVID patients frequently report:
The heterogeneity of these symptoms points to a systemic process rather than a single organ-level disease. This is consistent with the microcirculation and microclot framework: when capillary blood flow is impaired throughout the body, symptoms can emerge in any tissue or organ system.
Post-COVID is increasingly understood not as one disease but as the convergence of several interrelated pathological mechanisms. Research continues to refine this picture, but the following represent the most clinically relevant pathways identified to date.
One of the most significant findings in Post-COVID research is the presence of anomalous microclots in the blood of symptomatic patients. These are not ordinary blood clots. They are dense, amyloid-like fibrin structures that are resistant to normal fibrinolysis (the body’s clot-dissolving process).
Detection of microclots is emerging as a diagnostic marker, and their removal through therapeutic apheresis represents one of the most targeted treatment approaches currently available.
Damaged endothelium loses its ability to regulate vasodilation, becomes prothrombotic (promoting clot formation), and allows inflammatory molecules to migrate into surrounding tissues. This creates a vascular environment that perpetuates both microclot formation and tissue-level inflammation.
Endothelial repair is therefore a critical target in Post-COVID treatment, alongside microclot removal.
Growing evidence suggests that SARS-CoV-2 — or fragments of the virus including spike protein — can persist in tissues long after the acute infection resolves. Viral RNA and protein have been detected in gut tissue, lymph nodes, brain tissue, and vascular endothelium months after initial infection.
This viral persistence may continuously stimulate the immune system, drive chronic inflammation, and sustain endothelial damage. It may also explain why some patients experience a relapsing-remitting symptom pattern.
COVID-19 can profoundly disrupt the immune system. In Long COVID patients, we frequently observe: persistently elevated inflammatory cytokines (IL-6, TNF-alpha, interferon-gamma), T-cell exhaustion and impaired NK cell function, reactivation of latent herpes viruses (EBV, CMV, HHV-6), and emerging autoantibodies targeting the patient’s own tissues.
This state of chronic immune activation creates a feedback loop with endothelial damage and microclot formation, as inflammatory mediators further impair vascular function and coagulation balance.
SARS-CoV-2 is known to directly impact mitochondria — the cellular organelles responsible for energy production. In Post-COVID patients, impaired mitochondrial function results in reduced ATP synthesis, increased production of reactive oxygen species (oxidative stress), and compromised cellular respiration.
This explains the severe fatigue, exercise intolerance, and post-exertional malaise that characterize Long COVID. Impaired microcirculation further compounds the problem by reducing the delivery of oxygen and substrates that mitochondria need to function.
Through systematic analysis of patient blood samples and clinical outcomes, Dr. Jaeger’s work has identified fibrinoid microclots as a consistent finding in symptomatic Post-COVID patients. These microclots — visible under fluorescence microscopy when stained with thioflavin T — represent abnormal fibrin polymerization that resists the body’s normal clot-clearing mechanisms.
Her clinical experience has demonstrated a correlation between the burden of circulating microclots, the degree of microcirculatory impairment (measurable via sublingual capillaroscopy and other techniques), and the severity of patient symptoms. Patients undergoing targeted treatment — particularly therapeutic apheresis combined with anticoagulant support — have shown measurable improvements in both microcirculation parameters and clinical symptom scores.
This work represents an important and clinically relevant research direction. These mechanisms are actively under scientific investigation, and the treatment protocols at St. George Hospital continue to evolve as new evidence emerges from ongoing clinical studies.
Identifying the specific mechanisms at work in each individual patient is essential to designing an effective treatment plan. Standard blood tests often miss the pathology driving Long COVID symptoms.
At St. George Hospital, our diagnostic protocol includes microcirculation assessment, microclot detection, extended immune panels, mitochondrial function testing, viral persistence markers, autonomic nervous system evaluation, and gut microbiome analysis. This comprehensive approach allows us to build a precise picture of each patient’s condition.
Filters spike protein remnants, microclots, and inflammatory complexes that perpetuate post-COVID vascular and neurological symptoms.
Addresses tissue hypoxia and neuroinflammation -- two key mechanisms driving persistent post-COVID fatigue and brain fog.
Regenerates COVID-damaged mitochondria through controlled oxygen variation, restoring the cellular energy production that drives recovery.
Targeted immune modulation rebalances the dysregulated immune response that causes persistent post-COVID inflammation and autoimmunity.
Contact our team to discuss your Post-COVID symptoms and begin the path toward comprehensive diagnosis and targeted treatment.
